Stockscreener 앱 받기
51.75
1.02%
0.52
시간 외 거래:
51.75
Merus N V 주식(MRUS)의 최신 뉴스
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com UK
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
US FDA extends review of Merus' gene-targeting cancer therapy - Reuters
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
Harbor Capital Advisors Inc. Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Acquires Shares of 87,215 Merus (NASDAQ:MRUS) - MarketBeat
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Receives New Coverage from Analysts at UBS Group - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS) - Defense World
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain - Yahoo Finance
Analysts Set Merus (NASDAQ:MRUS) Target Price at $82.00 - Defense World
Market Resilience: Merus N.V (MRUS) Finishes Weak at 51.35, Down -1.57 - The Dwinnex
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
A company insider recently sold 2,500 shares of Merus N.V [MRUS]. Should You also Consider to Sale? - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Merus N.V (MRUS) - SETE News
Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
VP Controller, PAO Shuman Harry sale 2,500 shares of Merus N.V [MRUS] - Knox Daily
Market Highlights: Merus N.V (MRUS) Ends on a Low Note at 52.09 - The Dwinnex
There is no way Merus N.V (MRUS) can keep these numbers up - SETE News
What is the investor’s view on Merus N.V (MRUS)? - US Post News
Merus N.V (MRUS) receives a Buy rating from Truist - Knox Daily
Merus (NASDAQ:MRUS) Holdings Lowered by The Manufacturers Life Insurance Company - Defense World
Millennium Management LLC Has $14.39 Million Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Prepare Yourself for Liftoff: Merus N.V (MRUS) - SETE News
Guggenheim Raises Merus (NASDAQ:MRUS) Price Target to $111.00 - MarketBeat
Checking in on Merus N.V (MRUS) after recent insiders movement - Knox Daily
Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim - Defense World
Merus NV: Driving Innovation in Cancer Treatment with Shares Valued at $50.33 - NasdaqNewsFeed
Merus begins phase 3 trial for head and neck cancer therapy - Investing.com Canada
Merus (NASDAQ:MRUS) Shares Up 4.7% - Defense World
Merus's SWOT analysis: bispecific antibody developer's stock shows promise - Investing.com India
BMO maintains Merus $95 target on positive trial data By Investing.com - Investing.com Canada
Merus begins phase 3 trial for head and neck cancer therapy By Investing.com - Investing.com South Africa
Merus's SWOT analysis: bispecific antibody developer's stock shows promise By Investing.com - Investing.com Australia
BMO maintains Merus $95 target on positive trial data - Investing.com India
2.02%
0.47%
자본화:
|
볼륨(24시간):